Last reviewed · How we verify
Asprin
At a glance
| Generic name | Asprin |
|---|---|
| Also known as | ASA |
| Sponsor | Royan Institute |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes? (PHASE4)
- Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol (PHASE4)
- Adjuvant Aspirin Treatment for Colon Cancer Patients (PHASE3)
- A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose ASA and Metformin in Stage I-III Crc Patients (PHASE2)
- ASPIRIN: Neurodevelopmental Follow-up Trial
- Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction (PHASE1)
- SARS-CoV-2 and Acetylsalicylic Acid (SARA) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Asprin CI brief — competitive landscape report
- Asprin updates RSS · CI watch RSS
- Royan Institute portfolio CI